Background: Few studies evaluated the efficacy of pharmacological therapy for gastro-esophageal reflux disease (GERD) in newborns, whose safety has been questioned. Esophageal basal impedance (BI) is a marker of mucosal integrity, and treatment with proton pump inhibitors significantly increases BI in infants; however, no correlation with clinical improvement was reported. Aims: To evaluate the relationship between BI and other esophageal pH-impedance parameters and clinical response to therapy in newborns with GERD. Study design: Multicenter retrospective study. Subjects: Infants who received omeprazole or ranitidine for GERD. Outcome measures: Complete response to therapy was defined as symptom decrease by ≥50% compared to baseline, partial response as symptom decrease <50%, no response as no symptom decrease based on chart analysis. Response to therapy was assessed 2 and 4 weeks after the onset of therapy. Univariate and multivariate statistics were performed to assess associations between response to therapy and clinical/pH-impedance parameters. Results: We studied 60 infants (51 born preterm): 47 received omeprazole, 13 ranitidine. Response to therapy was associated with decreasing esophageal clearance time: odds ratio 0.308, 95%CI 0.126–0.753, p = 0.010 at 2 weeks, odds ratio 0.461, 95%CI 0.223–0.955, p = 0.037 at 4 weeks. Conclusions: Clinical response to therapy among infants with GERD was associated with esophageal clearance but not with esophageal BI level.

Response to therapy among neonates with gastro-esophageal reflux is associated with esophageal clearance

Salvatore S.;
2021

Abstract

Background: Few studies evaluated the efficacy of pharmacological therapy for gastro-esophageal reflux disease (GERD) in newborns, whose safety has been questioned. Esophageal basal impedance (BI) is a marker of mucosal integrity, and treatment with proton pump inhibitors significantly increases BI in infants; however, no correlation with clinical improvement was reported. Aims: To evaluate the relationship between BI and other esophageal pH-impedance parameters and clinical response to therapy in newborns with GERD. Study design: Multicenter retrospective study. Subjects: Infants who received omeprazole or ranitidine for GERD. Outcome measures: Complete response to therapy was defined as symptom decrease by ≥50% compared to baseline, partial response as symptom decrease <50%, no response as no symptom decrease based on chart analysis. Response to therapy was assessed 2 and 4 weeks after the onset of therapy. Univariate and multivariate statistics were performed to assess associations between response to therapy and clinical/pH-impedance parameters. Results: We studied 60 infants (51 born preterm): 47 received omeprazole, 13 ranitidine. Response to therapy was associated with decreasing esophageal clearance time: odds ratio 0.308, 95%CI 0.126–0.753, p = 0.010 at 2 weeks, odds ratio 0.461, 95%CI 0.223–0.955, p = 0.037 at 4 weeks. Conclusions: Clinical response to therapy among infants with GERD was associated with esophageal clearance but not with esophageal BI level.
Esophageal basal impedance; MII-pH; Newborn; Omeprazole; Preterm infant; Ranitidine
Nobile, S.; Meneghin, F.; Marchionni, P.; Noviello, C.; Salvatore, S.; Lista, G.; Carnielli, V. P.; Vento, G.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11383/2111364
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 4
  • ???jsp.display-item.citation.isi??? ND
social impact